SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cancer - Side effect drugs
An SI Board Since May 2002
Posts SubjectMarks Bans
57 4 0
Emcee:  John McCarthy Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
32[2000]-[XR9576]-[P-Glycoprotein Inhibitor][Protocol Number: 01-C-0091] ProtocolJohn McCarthy-5/18/2002
31[2001]-[XR9576]-[P-Glycoprotein Inhibitor][Phase 1 Study] Publication Year: 200John McCarthy-5/18/2002
30[2002]-[XR9576]-[P-Glycoprotein Inhibitor][XR9576/Tariquidar-How it works] P-I-John McCarthy-5/18/2002
29[2000]-[XR9576]-[P-Glycoprotein Inhibitor][Xenova Group plc] Press Releases BaJohn McCarthy-5/18/2002
28[2001]-[XR9576]-[P-Glycoprotein Inhibitor][A phase IIA pharmacokinetic study of John McCarthy-5/18/2002
27[2001]-[XR9576]-[P-Glycoprotein Inhibitor][Xenova today confirmed progress on itJohn McCarthy-5/18/2002
26[2001]-[XR9576]-[P-Glycoprotein Inhibitor][It had a high affinity for PGP] BPC John McCarthy-5/18/2002
25[2001]-[XR9576]-[P-Glycoprotein Inhibitor][In vitro prevention of the emergence John McCarthy-5/18/2002
24[2001]-[XR9576]-[P-Glycoprotein Inhibitor][A Phase IIA Pharmacokinetic Study of John McCarthy-5/18/2002
23[]John McCarthy-5/18/2002
22[2001]-[BNP7787]-[IPO Pulled] IPO Sector: Cancer drug developer BioNumerik PharJohn McCarthy-5/18/2002
21[2001]-[BNP7787]-[2001 - asco poster] conference-cast.comJohn McCarthy-5/18/2002
20[2000]-[BNP7787]-[("FDA") has granted fast track designation] SAN ANTJohn McCarthy-5/18/2002
19[1999]-[BNP7787]-[Design] Drug design and discovery can be a tedious task. It iJohn McCarthy-5/18/2002
18[2000]-[BNP7787]-[BioNumerik Pharmaceuticals, Inc. (Private)] BioNumerik PharmaJohn McCarthy-5/18/2002
17[1997]-[BNP7787]-[BioNumerik Treats First Patient with Novel Supercomputer-DevelJohn McCarthy-5/18/2002
16[2000]-[BNP7787]-[Pharmacokinetics of BNP7787 (dimesna) and its metabolite mesnaJohn McCarthy-5/18/2002
15[1998]-[BNP7787]-[Modulation of platinum-induced toxicities and therapeutic indeJohn McCarthy-5/18/2002
14[2002]-[BNP7787]-[Quantification of BNP7787 (dimesna) and its metabolite mesna iJohn McCarthy-5/18/2002
13[2000]-[BNP7787]-[Supercomputer-designed drug protects against chemotherapy toxiJohn McCarthy-5/18/2002
12[2002]-[BNP7787]-[BNP7787, a novel protector against platinum-related toxicitiesJohn McCarthy-5/18/2002
11[2000]-[BNP7787]-[Phase I dose-finding and pharmacokinetics (PK) study of BNP778John McCarthy-5/18/2002
10[2002]-[BNP7787]-[BioNumerik Pharmaceuticals, Inc.] BioNumerik Pharmaceuticals,John McCarthy-5/18/2002
9[2000]-[BNP7787]-[Phase 1 Trial] Record 1 Phase I Study of Dimesna in PatientsJohn McCarthy-5/18/2002
8[2002]-[BNP7787]-[Phase 3 Trial - Breast Cancer] BNP7787 vs Placebo for PreventJohn McCarthy-5/18/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News